VRTX · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 69 · Surprise 64 · No source text
Second-quarter 2026 total revenues increased 12% year over year to $3,333.9 million from $2,964.7 million, while first-half revenues increased 10% to $6,320.8 million from $5,734.9 million. Total CF product revenues rose 11% in the second quarter to $3,207.9 million and 8% in the first half to $6,122.9 million, led by ALYFTREK revenue of $573.6 million in the quarter, up 266%, partially offset by TRIKAFTA/KAFTRIO revenue declining 2% to $2,497.2 million. CASGEVY revenue increased 151% year over year to $76.4 million, and JOURNAVX revenue increased more than 300% to $49.6 million, indicating continued diversification beyond CF therapies. First-half ALYFTREK revenue increased 374% to $998.0 million, while first-half JOURNAVX revenue increased 491% to $78.6 million.
Key facts
- ALYFTREK product revenues in Q2 2026: $573.6 million, a 266% increase from $156.8 million in Q2 2025; six months ended ALYFTREK revenues: $998.0 million vs $210.7 million (374% increase) source
- CASGEVY product revenues recorded in Q2 2026: $76.4 million, representing a 78% increase compared to Q1 2026 and a 151% increase compared to Q2 2025 source
- JOURNAVX product revenues in Q2 2026: $49.6 million, representing a 71% increase compared to Q1 2026 and more than 300% increase compared to Q2 2025 source
- Recorded CASGEVY product revenues for the six months ended June 30, 2026: $119.3 million, up 167% compared to $44.6 million in the six months ended June 30, 2025 source
- Recorded JOURNAVX product revenues for the six months ended June 30, 2026: $78.6 million, up 491% compared to $13.3 million in the six months ended June 30, 2025 source
- Total revenues in the second quarter of 2026: $3.3 billion, as compared to $3.0 billion in the second quarter of 2025 source
- Total CF product revenues, net in Q2 2026: $3,207.9 million, up 11% from $2,901.6 million in Q2 2025; TRIKAFTA/KAFTRIO revenues in Q2 2026: $2,497.2 million (down 2% YoY) source
- Other revenues in Q2 2026 included a $20.6 million upfront payment from Ono and first half 2026 included a $10.0 million upfront payment from Zai source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +23.6% | ALYFTREK product revenues in Q2 2026: $573.6 million, a 266% increase from $156.8 million in Q2 2025; six months ended ALYFTREK revenues:… |
| revenue | positive | realized | +10.0% | Total revenues in the second quarter of 2026: $3.3 billion, as compared to $3.0 billion in the second quarter of 2025 |
| revenue | positive | realized | +9.2% | Total CF product revenues, net in Q2 2026: $3,207.9 million, up 11% from $2,901.6 million in Q2 2025; TRIKAFTA/KAFTRIO revenues in Q2… |
| revenue | positive | realized | +2.2% | Recorded CASGEVY product revenues for the six months ended June 30, 2026: $119.3 million, up 167% compared to $44.6 million in the six… |
| revenue | positive | realized | +2.0% | Recorded JOURNAVX product revenues for the six months ended June 30, 2026: $78.6 million, up 491% compared to $13.3 million in the six… |
| revenue | negative | realized | -1.5% | Total CF product revenues, net in Q2 2026: $3,207.9 million, up 11% from $2,901.6 million in Q2 2025; TRIKAFTA/KAFTRIO revenues in Q2… |